Draelos ZD, et al. - The intention of the authors was to gauge the long-term safety and efficacy of oxymetazoline cream 1.0% in rosacea patients with moderate to severe persistent erythema. Data disclosed that rebound effect was experienced by less than 1% of patients following treatment cessation. Sustained safety, tolerability, and efficacy was illustrated of oxymetazoline for moderate to severe persistent erythema of rosacea.

Methods

• During this research, patients applied oxymetazoline once daily for 52 weeks.
• Treatment-emergent adverse events (TEAEs), skin blanching, inflammatory lesion counts, telangiectasia, disease severity, and rebound effect served as the safety assessments.
• In order to gauge the efficacy, experts used the Clinician Erythema Assessment (CEA) and Subject Self-Assessment (SSA) composite score at 3 and 6 hours postdose on day 1 and weeks 4, 26, and 52.

Results

• Out of 440 patients, 8.2% reported treatment-related TEAEs, with application-site dermatitis, paresthesia, pain, and pruritus being most common.
• Findings revealed the discontinuation rate to be 3.2% due to adverse events (mostly application-site TEAEs).
• With regard to skin blanching, inflammatory lesions, or telangiectasia, there were no clinically significant variations.
• As per the outcomes, 36.7% and 43.4% of patients displayed ≥2-grade composite improvement from baseline in both CEA and SSA at 3 and 6 hours postdose, respectively at week 52.
• After treatment cessation, less than 1% of patients presented with rebound effect.